181 related articles for article (PubMed ID: 26650078)
1. Health Gains and Financial Protection from Pneumococcal Vaccination and Pneumonia Treatment in Ethiopia: Results from an Extended Cost-Effectiveness Analysis.
Johansson KA; Memirie ST; Pecenka C; Jamison DT; Verguet S
PLoS One; 2015; 10(12):e0142691. PubMed ID: 26650078
[TBL] [Abstract][Full Text] [Related]
2. Health gains and financial risk protection afforded by public financing of selected interventions in Ethiopia: an extended cost-effectiveness analysis.
Verguet S; Olson ZD; Babigumira JB; Desalegn D; Johansson KA; Kruk ME; Levin CE; Nugent RA; Pecenka C; Shrime MG; Memirie ST; Watkins DA; Jamison DT
Lancet Glob Health; 2015 May; 3(5):e288-96. PubMed ID: 25889470
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea.
Sohn HS; Suh DC; Jang E; Kwon JW
J Manag Care Pharm; 2010; 16(1):32-45. PubMed ID: 20044845
[TBL] [Abstract][Full Text] [Related]
4. Public finance of rotavirus vaccination in India and Ethiopia: an extended cost-effectiveness analysis.
Verguet S; Murphy S; Anderson B; Johansson KA; Glass R; Rheingans R
Vaccine; 2013 Oct; 31(42):4902-10. PubMed ID: 23871824
[TBL] [Abstract][Full Text] [Related]
5. Health gains and financial risk protection afforded by public financing of selected malaria interventions in Ethiopia: an extended cost-effectiveness analysis.
Assebe LF; Kwete XJ; Wang D; Liu L; Norheim OF; Jbaily A; Verguet S; Johansson KA; Tolla MT
Malar J; 2020 Jan; 19(1):41. PubMed ID: 31973694
[TBL] [Abstract][Full Text] [Related]
6. Health Gains and Financial Protection Provided by the Ethiopian Mental Health Strategy: an Extended Cost-Effectiveness Analysis.
Johansson KA; Strand KB; Fekadu A; Chisholm D
Health Policy Plan; 2017 Apr; 32(3):376-383. PubMed ID: 27935798
[TBL] [Abstract][Full Text] [Related]
7. Health gains and financial risk protection: an extended cost-effectiveness analysis of treatment and prevention of diarrhoea in Ethiopia.
Pecenka CJ; Johansson KA; Memirie ST; Jamison DT; Verguet S
BMJ Open; 2015 May; 5(4):e006402. PubMed ID: 25941175
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of childhood pneumococcal vaccination program in Ethiopia: results from a quasi-experimental evaluation.
Kebede TT; Svensson M; Addissie A; Trollfors B; Andersson R
BMC Public Health; 2019 Aug; 19(1):1078. PubMed ID: 31399030
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness Analysis of Pneumococcal and Influenza Vaccines Administered to Children Less Than 5 Years of Age in a Low-Income District of Bogota, Colombia.
Lara C; De Graeve D; Franco F
Value Health Reg Issues; 2018 Dec; 17():21-31. PubMed ID: 29626706
[TBL] [Abstract][Full Text] [Related]
10. Health gains and financial protection from human papillomavirus vaccination in Ethiopia: findings from a modelling study.
Portnoy A; Sweet S; Desalegn D; Memirie ST; Kim JJ; Verguet S
Health Policy Plan; 2021 Jun; 36(6):891-899. PubMed ID: 33942850
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013.
Sibak M; Moussa I; El-Tantawy N; Badr S; Chaudhri I; Allam E; Baxter L; Abo Freikha S; Hoestlandt C; Lara C; Hajjeh R; Munier A
Vaccine; 2015 May; 33 Suppl 1():A182-91. PubMed ID: 25919159
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness and Health Benefits of Pediatric 23-valent Pneumococcal Polysaccharide Vaccine, 7-valent Pneumococcal Conjugate Vaccine and Forecasting 13-valent Pneumococcal Conjugate Vaccine in China.
Mo X; Gai Tobe R; Liu X; Mori R
Pediatr Infect Dis J; 2016 Nov; 35(11):e353-e361. PubMed ID: 27753771
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
[TBL] [Abstract][Full Text] [Related]
14. Estimating the economic impact of pneumococcal conjugate, Haemophilus influenzae type b and rotavirus vaccines in India: National and state-level analyses.
Constenla D; Liu T
Vaccine; 2019 Dec; 37(52):7547-7559. PubMed ID: 31607600
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of introducing the pneumococcal conjugate vaccine for children under 5 years in the Islamic Republic of Iran.
Ezoji K; Yaghoubi M; Nojomi M; Mahmoody S; Zahraie SM; Moradi-Lakeh M; Tabatabaei SR; Karimi A
East Mediterr Health J; 2019 Nov; 25(10):686-697. PubMed ID: 31774134
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of pneumococcal conjugate vaccination in Georgia.
Komakhidze T; Hoestlandt C; Dolakidze T; Shakhnazarova M; Chlikadze R; Kopaleishvili N; Goginashvili K; Kherkheulidze M; Clark AD; Blau J
Vaccine; 2015 May; 33 Suppl 1():A219-26. PubMed ID: 25919165
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation of pneumococcal conjugate vaccination in The Gambia.
Kim SY; Lee G; Goldie SJ
BMC Infect Dis; 2010 Sep; 10():260. PubMed ID: 20815900
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B
Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641
[TBL] [Abstract][Full Text] [Related]
19. An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China.
Levin CE; Sharma M; Olson Z; Verguet S; Shi JF; Wang SM; Qiao YL; Jamison DT; Kim JJ
Vaccine; 2015 Jun; 33(24):2830-41. PubMed ID: 25770785
[TBL] [Abstract][Full Text] [Related]
20. Pneumococcal conjugate vaccination in The Gambia: health impact, cost effectiveness and budget implications.
Pecenka C; Usuf E; Hossain I; Sambou S; Vodicka E; Atherly D; Mackenzie G
BMJ Glob Health; 2021 Dec; 6(12):. PubMed ID: 34916274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
